We are developing biomarker-guided precision oligonucleotide therapies for diseases with high unmet need. We are a data-first team of scientists on a mission to create effective therapies, breaking the code of many diseases. David also served as the CSO of MiraDx, spearheading projects to commercialize germline DNA biomarkers in oncology.
Waltham, United States
Founded in 2016
1-10 Employees
Working industry
Biotechnology
Type of company
Manufacturer
Ownership structure
Privately Held
Locations
1 Headquarter
Number of products
1 Product
Specialised areas
Biotechnology
Gatehouse Bio offers a wide range of products and services
Product
Technology - Gatehouse Bio
Go to product >
An estimation about the ESG values based on digital data and signals. Important: The ESG scores are only based on information about the country, not the actual company itself
Country:
United States
Overall risk estimation:
Low
The ESG Data of countries are based on public sources
Environment
D
Grade (A-E)
View details
Social
A
Grade (A-E)
View details
Governance
A
Grade (A-E)
View details
Gatehouse Bio operates in 1 country around the world
Get an overview of the locations of Gatehouse Bio
Location
Country
State
City
Headquarter
United States
Massachusetts
Waltham
Some frequent questions that have been asked about Gatehouse Bio
Where is Gatehouse Bio located?
The company headquarter of Gatehouse Bio is located in Waltham, Massachusetts, United States. It's worth noting, that the company may have more locations
How many employees does Gatehouse Bio approximately have?
As of the latest available information Gatehouse Bio has around 1-10 employees worldwide.
When was Gatehouse Bio founded?
Gatehouse Bio was founded in 2016
In which industries does Gatehouse Bio mainly work?
The company Gatehouse Bio has it's main focus in the industries of Biotechnology
Check out some interesting alternative companies to Gatehouse Bio
MEDiC
San Carlos, United States
1-10 Employees
2019
We are building a world-class team of scientists and engineers dedicated to designing the revolutionary platform that can fundamentally change the way how cancer drugs are developed. Cancer biomarker is the key to stratify patients for oncology drugs, but the current drug development system misses many potential biomarkers and novel drug targets.
Remix Therapeutics
Cambridge, United States
11-50 Employees
2019
Our breakthrough science provides a path to identify small molecules that impact the expression of disease driving mRNAs and proteins. With an in-house technology platform built from scratch, we have rapidly generated multiple drug discovery programs that are advancing towards the clinic.
Biofidelity
Cambridge, United Kingdom
11-50 Employees
2019
Our mission is to transform human health and the world we live in by developing innovative technologies that unleash the potential of genomics. We are thrilled to announce the launch of ASPYRE-Lung, reducing the time to obtain vital biomarker data from weeks to days. At Biofidelity, we believe every patient deserves the best treatment options. We are committed to overcoming barriers that have prevented hundreds of thousands of patients from experiencing the exceptional benefits of targeted therapies. Biofidelity’s novel technology removes the noise from genomic data, providing only the information needed to make decision-making less complex, faster and more accurate. Our mission is to transform human health and the world we live in, and we won’t stop until there is genomics for all. By eliminating uninformative DNA, our products massively reduce the time, cost, and complexity of genomic analysis, improving accuracy and enabling faster and simpler decision-making. Dr Levin is a US-trained oncologist and hematologist with over 15 years’ industry experience in translational medicine and drug development, leading clinical development and medical affairs as well as supporting business development.
Wave Life Sciences
Boston, United States
101-250 Employees
2012
We are leveraging a toolkit of RNA-targeting modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. We are advancing a pipeline of first- or best-in-class therapeutics with life-changing potential, including in Alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, Huntington’s disease, and obesity. We are seeking bold, enterprising individuals to join our team. Our team includes some of the world’s most respected oligonucleotide chemists, drug development experts, and dedicated patient advocates.
Ilico Genetics
Santiago, Chile
1-10 Employees
-
We are a multinational, intergenerational, and multidisciplinary team with proven experience in cancer research, laboratory operations, and business management. Our aspiration is to impact the lives of patients and their families by developing innovative genomic solutions.
Dayton Therapeutics
Steinhausen, Switzerland
1-10 Employees
-
We are scaling up the identification and development of clinical compounds using proprietary oncologist know-how by amplifying the process with AI and data mining to systematically pursue high-yield candidates for cancer indications of large unmet medical need. We are oncologists, scientists and entrepreneurs, and we believe in the power of innovation to unlock new therapies for patients in need of therapeutic options.